FDA expands Keytruda approval for first-line NSCLC treatment

FDA expands Keytruda approval for first-line NSCLC treatment

Submitted by admin on April 12, 2019 - 11:26am
Source: 
Pharmaforum
News Tags: 
Merck
Keytruda
FDA
non-small cell lung cancer
Headline: 
FDA expands Keytruda approval for first-line NSCLC treatment
snippet: 

Cancer drug Keytruda can now be used as a first-line treatment for patients with stage three non-small cell lung cancer (NSCLC), whose treatment options are limited.

Do Not Allow Advertisers to Use My Personal information